Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.64 |
| ▸ | CTSA | P10619 | 1/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8882297 | 0.99 | EGLN2 (0.62) | EGLN2FTOCTSAEGLN1GAA | |
| SCHEMBL10710283 | 0.84 | CTSA (0.54) | EGLN2FTOCTSAPOLBADORA2A | |
| SCHEMBL3488692 | 0.84 | CTSA (0.50) | EGLN2FTOCTSAGAAPOLB | |
| SCHEMBL8883269 | 0.83 | CTSA (0.46) | EGLN2FTOCTSAEGLN1POLB | |
| SCHEMBL8883297 | 0.82 | BRD4 (0.47) | EGLN2FTOCTSAEGLN1POLB | |
| SCHEMBL30003357 | 0.82 | KMT2A (0.58) | CTSAGAASMN1; SMN2MAPT | |
| SCHEMBL8809859 | 0.82 | EGLN2 (0.59) | EGLN2FTOEGLN1MAPT | |
| SCHEMBL18245565 | 0.81 | CTSD (0.56) | CTSAGAASMN1; SMN2ADORA2AKDM4E | |
| SCHEMBL8883000 | 0.81 | MEN1 (0.46) | EGLN2FTOCTSAPOLBADORA2A | |
| SCHEMBL24598452 | 0.81 | CTSA (0.51) | CTSAGAAPOLBADORA2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-8124582-B2 | stabilizing alpha subunit of hypoxia inducible factor protein (HIF alpha ), thereby regulating glucose metabolism; preventing or treating hyperglycemia, obesity, hypertension, hyperlipidemia, nephropathy, neuropathy, retinopathy, impaired glucose tolerance, atherosclerosis, and vascular disease | FIBROGEN, INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2327399-A1 | Treatment of hypertension | Fibrogen, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2004108121-A1 | USE OF HIF ALPHA STABILIZERS FOR ENHANCING ERYTHROPOIESIS | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1463823-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN2 3/4885FTO 1391/4885CTSA 2938/4885 |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | EGLN2 3/4885FTO 3968/4885CTSA 206/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN2 370/4885FTO 4661/4885CTSA 546/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN2 9/4885FTO 1546/4885CTSA 579/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN2 7/4885FTO 1235/4885CTSA 1167/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN2 3/4885FTO 1391/4885CTSA 2938/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN2 9/4885FTO 1546/4885CTSA 579/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN2 3/4885FTO 2629/4885CTSA 799/4885 |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN2 9/4885FTO 1546/4885CTSA 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.